Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target

Published: Thursday, March 15, 2012
Last Updated: Wednesday, March 14, 2012
Bookmark and Share
New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK.

UCB and Domainex Ltd have jointly published the results of a collaboration in the field of cancer drug discovery.

Working together, the two companies have developed an experimental system to study the three-dimensional structure of Mitogen-activated protein kinase kinase (MAPKK, also known as MEK), a protein which is over-active in many human cancers.

Using the high-resolution structural information, UCB scientists were able to design a novel class of molecules which inhibit MEK and which have the potential to combat cancer.

The key step in this work, reported in the latest edition of the Journal of Structural Biology, used Domainex’s Combinatorial Domain Hunting (CDH) technology to identify a form of the MEK protein which can be produced in large quantities and which is suitable for structure-based drug discovery.

In the case of MEK, this was challenging because conventional methods proved unsuccessful, however Domainex’s CDH technology allowed the problem to be solved rapidly.

“The partnership with Domainex has been invaluable for our MEK discovery program. Successful collaborations, such as this, are a key part of UCB’s innovative and cutting-edge research. We hope that the novel class of MEK inhibitors which the UCB team discovered will bring benefits to patients,” said Neil Weir, Senior Vice President, Discovery Research UCB.

CDH is a biotechnological method that enables the identification of proteins for drug discovery and other applications. It involves the random fragmentation of DNA, and the screening of thousands of DNA fragments to identify those that produce large amounts of the protein of interest.

Trevor Perrior, Research Director at Domainex said: “Producing high-quality protein is crucial for successful drug research. Once again, Domainex’s CDH technology has proven to be invaluable, and the rapid identification of the best form of MEK from tens of thousands of other possibilities further validates our technology. We were extremely pleased that UCB could successfully utilize the constructs to generate high-resolution structural information and, most importantly, to use it to optimize their chemical series.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
Crystals, Super Magnets in Drug Discovery
Scientists have produced larger superparamagnetic crystals that could revolutionise drug delivery.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Snapshots of Chemical Flipping a Biological Switch
X-ray laser gets first real-time snapshots of a chemical flipping a biological switch, opening new path to understanding how RNA works.
Uncovering Elusive Proteins
Researchers have determined the complete structure of elusive proteins, known as tetraspanins, for the first time.
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Study Unocovers Cancer-Linked Protein’s Associates
Researchers have developed a new list of nearly 100 potential partners of a cancer-linked enzyme by studying its interactions with other proteins.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!